|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment显示文摘Ischemia/reperfusion injury is an unavoidable relevant consequence after kidney transplantation and influences short term as well as long-term graft outcome. Clinically ischemia/reperfusion injury is associated with delayed graft function, graft rejection, chronic rejection and chronic graft dysfunction. Ischemia/reperfusion affects many regulatory systems at the cellular level as well as in the renal tissue that result in a distinct inflammatory reaction of the kidney graft. Underlying factors of ischemia reperfusion include energy metabolism, cellular changes of the mitochondria and cellular membranes, initiation of different forms of cell death-like apoptosis and necrosis together with a recently discovered mixed form termed necroptosis. Chemokines and cytokines together with other factors promote the inflammatory response leading to activation of the innate immune system as well as the adaptive immune system. If the inflammatory reaction continues within the graft tissue, a progressive interstitial fibrosis develops that impacts long-term graft outcome. It is of particular importance in kidney transplantation to understand the underlying mechanisms and effects of ischemia/reperfusion on the graft as this knowledge also opens strategies to prevent or treat ischemia/reperfusion injury after transplantation in order to improve graft outcome. | Maurizio Salvadori Giuseppina Rosso Elisabetta Bertoni | 2015 | World Journal of Transplantation2015，5，2： | 43 |
| 2 | Pathogenesis, prevention, diagnosis and treatment of breast cancer显示文摘Breast cancer is the most common cancer affecting women worldwide. Prediction models stratify a woman's risk for developing cancer and can guide screening recommendations based on the presence of known and quantifiable hormonal, environmental, personal, or genetic risk factors. Mammography remains the mainstay breast cancer screening and detection but magnetic resonance imaging and ultrasound have become useful diagnostic adjuncts in select patient populations. The management of breast cancer has seen much refinement with increased specialization and collaboration with multidisciplinary teams that include surgeons, oncologists, radiation oncologists, nurses, geneticist, reconstructive surgeons and patients. Evidence supports a less invasive surgical approach to the staging and management of the axilla in select patients. In the era of patient/tumor specific management, the advent of molecular and genomic profiling is a paradigm shift in the treatment of a biologically heterogenous disease. | Rupen Shah Kelly Rosso S David Nathanson | 2014 | World Journal of Clinical Oncology2014，5，3： | 17 |
| 3 | Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is one of most common malignancies in the world. Systemic treatments for HCC, particularly for advanced stages, are limited by the drug resistance phenomenon which ultimately leads to therapy failure. Recent studies have indicated an association between drug resistance and the existence of the cancer stem cells (CSCs) as tumor initiating cells. The CSCs are resistant to conventional chemotherapies and might be related to the mechanisms of the ATP Binding Cassette (ABC) transporters and alterations in the CSCs signaling pathways. Therefore, to contribute to the development of new HCC treatments, further information on the characterization of CSCs, the modulation of the ABC transporters expression and function and the signaling pathway involved in the self renewal, initiation and maintenance of the cancer are required. The combination of transporters modulators/inhibitors with molecular targeted therapies may be a potent strategy to block the tumoral progression. This review summarizes the association of CSCs, drug resistance, ABC transporters activities and changes in signaling pathways as a guide for future molecular therapy for HCC. | Caecilia HC Sukowati Natalia Rosso Lory S Crocè Claudio Tiribelli | 2010 | World Journal of Hepatology2010，2，3： | 16 |
| 4 | Translational approaches: From fatty liver to non-alcoholic steatohepatitis显示文摘Over the past few decades, non-alcoholic fatty liver disease(NAFLD) has become one, if not the most common,cause of chronic liver disease affecting both adults and children. The increasing number of cases at an early age is the most worrying aspect of this pathology, since it provides more time for its evolution. The spectrum of this disease ranges from liver steatosis to steatohepatitis, fibrosis and in some cases, hepatocellular carcinoma. NAFLD may not always be considered a benign disease and hepatologists must be cautious in the presence of fatty liver. This should prompt the use of the available experimental models to understand better the pathogenesis and to develop a rational treatment of a disease that is dangerously increasing. In spite of the growing efforts, the pathogenesis of NAFLD is still poorly understood. In the present article we review the most relevant hypotheses and evidence that account for the progression of NAFLD to non-alcoholic steatohepatitis(NASH) and fibrosis. The available in vitro and in vivo experimental models of NASH are discussed and revised in terms of their validity in translational studies. These studies must be aimed at the discovery of the still unknown triggers or mediators that induce the progression of hepatic inflammation, apoptosis and fibrosis. | Natalia Rosso Norberto C Chavez-Tapia Claudio Tiribelli Stefano Bellentani | 2014 | World Journal of Gastroenterology2014，20，27： | 14 |
| 5 | Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012显示文摘 | J. Ferlay E. Steliarova-Foucher J. Lortet-Tieulent S. Rosso J.W.W. Coebergh H. Comber D. Forman F. Bray | 2013 | European Journal of Cancer2013，，6： | 13 |
| 6 | Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis显示文摘The nonalcoholic fatty liver disease(NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD encompasses a wide histological spectrum ranging from benign simple steatosis to non-alcoholic steatohepatitis(NASH). Sustained inflammation in the liver is critical in this process. Hepatic macrophages, including liver resident macropaghes(Kupffer cells), monocytes infiltrating the injured liver, as well as specific lymphocytes subsets play a pivotal role in the initiation and perpetuation of the inflammatory response, with a major deleterious impact on the progression of fatty liver to fibrosis. During the last years, Th17 cells have been involved in the development of inflammation not only in liver but also in other organs, such as adipose tissue or lung. Differentiation of a na?ve T cell into a Th17 cell leads to pro-inflammatory cytokine and chemokine production with subsequent myeloid cell recruitment to the inflamed tissue. Th17 response can be mitigated by T regulatory cells that secrete anti-inflammatory cytokines. Both T cell subsets need TGF-β for their differentiation and a characteristic plasticity in their phenotype may render them new therapeutic targets. In this review, we discuss the role of the Th17 pathway in NAFLD progression to NASH and to liver fibrosis analyzing different animal models of liver injury and human studies. | Carla Melisa Chackelevicius Sabrina Eliana Gambaro Claudio Tiribelli Natalia Rosso | 2016 | World Journal of Gastroenterology2016，22，41： | 10 |
| 7 | Update on immunoglobulin A nephropathy, Part I: Pathophysiology显示文摘Immunoglobulin A(Ig A) nephropathy is one of the most common glomerulonephritis and its frequency is probably underestimated because in most patients the disease has an indolent course and the kidney biopsy is essential for the diagnosis. In the last years its pathogenesis has been better identified even if still now several questions remain to be answered. The genetic wide association studies have allowed to identifying the relevance of genetics and several putative genes have been identified. The genetics has also allowed explaining why some ancestral groups are affected with higher frequency. To date is clear that IgA nephropathy is related to auto antibodies against immunoglobulin A1(IgA 1) with poor O-glycosylation. The role of mucosal infections is confirmed, but which are the pathogens involved and which is the role of Toll-like receptor polymorphism is less clear. Similarly to date whether the disease is due to the circulating immunocomplexes deposition on the mesangium or whether the antigen is already present on the mesangial cell as a 'lanthanic' deposition remains to be clarified. Finally also the link between the mesangial and the podocyte injury and the tubulointerstitial scarring, as well as the mechanisms involved need to be better clarified. | Maurizio Salvadori Giuseppina Rosso | 2015 | World Journal of Nephrology2015，4，4： | 6 |
| 8 | Liver Med23 ablation improves glucose and lipid metabolism through modulating FOX01 activity显示文摘 | Yajing Chu Leonardo Gomez Rosso Ping Huang Zhichao Wang Yichi Xu Xiao Yao Menghan Bao Jun Yan Haiyun Song Gang Wang | 2014 | Cell Research2014，24，10： | 5 |
| 9 | Strigolactone Analogs as Molecular Probes in Chasing the (SLs) Receptor/s: Design and Synthesis of Fluorescent Labeled Molecules显示文摘原来作为涉及 plantparasite 相互作用的 allelochemicals 识别了,更最近, Strigolactones (SL ) 被显示了在在植物和 mycorrhizal 真菌之间的根围通讯起多重关键作用。甚至更最近神经质的角色被归功于到拓宽这些相对简单的分子的生物影响的 SL。尽管有关键并且 multifaceted SL 的生物角色,绑如此的活跃分子的受体上没有数据,既不在生产植物也不在寄生杂草或 AM 真菌。SL 的通常认为的受体的信息能借助于结构、分子、基因的途径被聚集。我们这个话题上的贡献是设计和合成荧光灯在受体的 vivo 为察觉要用作探针的标记的 SL 类似物。通常认为的受体结构的知识将在为农业应用要求了的自然底层的类似物上增加研究。 | Cristina Prandi Helena Rosso Beatrice Lace Ernesto G. Occhiatot Alberto Oppedisano Silvia Tabasso Gabriele Alberto Marco Blangetti | 2013 | Molecular Plant2013，6，1： | 5 |
| 10 | Use of chondral fragments for one stage cartilage repair: A systematic review显示文摘AIM: To investigate the state of the art regarding Cartilage Autograft Implantation System(CAIS) or Particulated Juvenile Allograft Cartilage(PJAC).METHODS: The authors searched the English literature regarding CAIS and PJAC. The search strategy was:(particulated cartilage) OR autologous cartilage fragments. All basic science articles were included. Clinical articles with less than 10 patients treated and less than 6 mo of follow-up were excluded. With these criteria, a total of 17 articles were available for the present review. RESULTS: PJAC and CAIS are relatively novel techniques for cartilage repair. Good basic science evidence was described to support the concept. Although the preliminary clinical reports show encouraging results, clinical data are still limited, especially for CAIS. The indications for both techniques need to be precisely defined(age of the patients, size of the lesion, and involvement of the subchondral bone), together with other debated issues. CONCLUSION: In conclusion, the authors can state that encouraging preliminary results are available for both techniques. However, further studies are necessary to precisely determine the indications, surgical techniques, and long term outcomes for PJAC and CAIS. | Davide Edoardo Bonasia Antongiulio Marmotti Federica Rosso Gianluca Collo Roberto Rossi | 2015 | World Journal of Orthopedics2015，6，11： | 5 |
| 11 | Reclassification of membranoproliferative glomerulonephritis:Identification of a new GN:C3GN显示文摘This review revises the reclassification of the membranoproliferative glomerulonephritis(MPGN) after the consensus conference that by 2015 reclassified all the glomerulonephritis basing on etiology and pathogenesis, instead of the histomorphological aspects. After reclassification, two types of MPGN are to date recognized: The immunocomplexes mediated MPGN and the complement mediated MPGN. The latter type is more extensively described in the review either because several of these entities are completely new or because the improved knowledge of the complement cascade allowed for new diagnostic and therapeutic approaches. Overall the complement mediated MPGN are related to acquired or genetic cause. The presence of circulating auto antibodies is the principal acquired cause. Genetic wide association studies and family studies allowed to recognize genetic mutations of different types as causes of the complement dysregulation. The complement cascade is a complex phenomenon and activating factors and regulating factors should be distinguished. Genetic mutations causing abnormalities either in activating or in regulating factors have been described. The diagnosis of the complement mediated MPGN requires a complete study of all these different complement factors. As a consequence, new therapeutic approaches are becoming available. Indeed, in addition to a nonspecific treatment and to the immunosuppression that has the aim to block the auto antibodies production, the specific inhibition of complement activation is relatively new and may act either blocking the C5 convertase or the C3 convertase. The drugs acting on C3 convertase are still in different phases of clinical development and might represent drugs for the future. Overall the authors consider that one of the principal problems in finding new types of drugs are both the rarity of the disease and the consequent poor interest in the marketing and the lack of large international cooperative studies. | Maurizio Salvadori Giuseppina Rosso | 2016 | World Journal of Nephrology2016，5，4： | 3 |
| 12 | Complement involvement in kidney diseases:From physiopathology to therapeutical targeting显示文摘Complement cascade is involved in several renal diseases and in renal transplantation. The different components of the complement cascade might represent an optimal target for innovative therapies. In the first section of the paper the authors review the physiopathology of complement involvement in renal diseases and transplantation. In some cases this led to a reclassification of renal diseases moving from a histopathological to a physiopathological classification. The principal issues afforded are: renal diseases with complement over activation, renal diseases with complement dysregulation, progression of renal diseases and renal transplantation. In the second section the authors discuss the several complement components that could represent a therapeutic target. Even if only the anti C5 monoclonal antibody is on the market, many targets as C1, C3, C5 a and C5 a R are the object of national or international trials. In addition, many molecules proved to be effective in vitro or in preclinical trials and are waiting to move to human trials in the future. | Maurizio Salvadori Giuseppina Rosso Elisabetta Bertoni | 2015 | World Journal of Nephrology2015，4，2： | 3 |
| 13 | Preparation and Structural Characterization of Rapidly Solidified Al-Cu Alloys显示文摘Rapidly solidified Al100-x—Cux alloys(x = 5,10,1 5,25,35 wt%) were prepared and analyzed.High cooling rate increased the Cu solubility in 9.-AI matrix.The influence of the cooling rate on Cu solubility extension in Al was experimentally simulated.Thus the pouring was performed in metallic die and by melt spinning-low pressure(MSLP) technique.Melt processing by liquid quenching was performed using a self-designed melt spinning set-up which combined the cooling technology of a melt jet on the spinning disc with the principle of the mold feeding from low pressure casting technology.The thickness of the melt-spun ribbons was in the range of30—70 μm.The cooling rate provided by MS-LP was within 105—106 K/s after the device calibration.The obtained alloys were characterized from structural,thermal and mechanical point of view.Optical microscopy and scanning electron microscopy were employed for the microstructural characterization which was followed by X-ray analysis.The thermal properties were evaluated by dilatometric and differential scanning calorimetric measurements.Vickers microhardness measurements were performed in the study.In the case of the hypereutectic alloy with 35 wt%Cu obtained by MS-LP method,the microhardness value increased by 45%compared to the same alloy obtained by gravity casting method.This was due to the extended solubility of the alloying element in the α-AI solid solution. | Iuliana Lichioiu Ildiko Peter Bela Varga Mario Rosso | 2014 | Journal of Materials Science & Technology2014，30，4： | 3 |
| 14 | Update on immunoglobulin a nephropathy.Part Ⅱ:Clinical,diagnostic and therapeutical aspects显示文摘Immunoglobulin A nephropathy(IgAN) is characterized by different clinical manifestations and by long-term different outcomes. Major problem for the physicians is to understanding which patients are at risk of a disease evolution and to prescribe the right therapy to the right patients. Indeed, in addition to patients with a stable disease with no trend to evolution or even with a spontaneous recovery, patients with an active disease and patients with a rapidly evolving glomerulonephritis are described. Several histopathological, biological and clinical markers have been described and are currently used to a better understanding of patients at risk, to suggest the right therapy and to monitor the therapy effect and the Ig AN evolution over time. The clinical markers are the most reliable and allow to divide the Ig AN patients into three categories: The low risk patients, the intermediate risk patients and the high risk patients. Accordingly, the therapeutic measures range from no therapy with the only need of repeated controls, to supportive therapy eventually associated with low dose immunosuppression, to immunosuppressive treatment in the attempt to avoid the evolution to end stage renal disease. However the current evidence about the different therapies is still matter of discussion. New drugs are in the pipeline and are described. They are object of randomized controlled trials, but studies with a number of patients adequately powered and with a long follow up are needed to evaluate efficacy and safety of these new drugs. | Maurizio Salvadori Giuseppina Rosso | 2016 | World Journal of Nephrology2016，5，1： | 3 |
| 15 | Reflectance properties and physiological responses of Salicornia virginica to heavy metal and petroleum contamination显示文摘 | Pablo H. Rosso James C. Pushnik Mui Lay Susan L. Ustin | 2005 | Environmental Pollution2005，，2： | 3 |
| 16 | Root associations in Austrocedrus forests and seasonal dynamics of arbuscular mycorrhizas显示文摘 | S. Fontenla R. Godoy P. Rosso M. Havrylenko | 1998 | Mycorrhiza1998，，： | 2 |
| 17 | J-Point Elevation in Survivors of Primary Ventricular Fibrillation and Matched Control Subjects显示文摘 | Raphael Rosso Evgeni Kogan Bernard Belhassen Uri Rozovski Melvin M. Scheinman David Zeltser Amir Halkin Arie Steinvil Karin Heller Michael Glikson Amos Katz Sami Viskin | 2008 | Journal of the American College of Cardiology2008，，15： | 2 |
| 18 | Pancreatic cancer:New hopes after first line treatment显示文摘Pancreatic cancer is the fourth leading cause of cancerrelated death worldwide.Extensive research has yielded advances in first-line treatment strategies,but there is no standardized second-line therapy.In this review,we examine the literature trying to establish a possible therapeutic algorithm. | Francesca Aroldi Paola Bertocchi Giordano Savelli Edoardo Rosso Alberto Zaniboni | 2016 | World Journal of Gastrointestinal Oncology2016，8，9： | 2 |
| 19 | 非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的相互作用显示文摘【据《J Hepatol》2019年11月报道】题:非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的相互作用(作者Rosso C等)非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)的发病机制可能是由于紊乱的代谢环境与肝脏炎症和纤维化的局部介质之间的相互作用。该研究旨在阐明巨噬细胞活化、靶器官/组织胰岛素抵抗(IR)与肝损伤之间的相互作用。 | 赵优优 高普均 ROSSO C KAZANKOV K YOUNES R | 2020 | 临床肝胆病杂志2020，36，3： | 2 |
| 20 | A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases显示文摘 | Daniel Jaeck Elie Oussoultzoglou Edoardo Rosso Michel Greget Jean-Christophe Weber Philippe Bachellier | 2004 | Annals of Surgery2004，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员